Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich: Oct 18, 2007

Sigma-Aldrich has introduced the N-Ter nanoparticle siRNA transfection system.
According to the company, the system uses a stable nanoparticle, rather than a lipid-based transfection reagent, that is formed by combining siRNA with the N-Ter peptide.
"Traditional lipid-based siRNA transfection reagents exhibit a number of drawbacks, including high cell death rates and a limited ability to deliver siRNA into a variety of cell types, such as primary, neuronal, differentiated, and non-dividing cells," Tim Fleming, director of global commercial marketing at Sigma-Aldrich, said in a statement. "Our goal is to introduce a reagent into the scientific community that effectively bypasses these historic limitations and enables siRNA transfection to be performed in a wider variety of model systems."

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.